TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
ProKidney ( (PROK) ) has issued an update.
ProKidney Corp. announced that on October 17, 2025, it entered into a new purchase and sale agreement with Northpoint Development, LLC to sell its property in Greensboro, North Carolina for approximately $19.1 million in cash. This transaction, which follows a previously terminated agreement with Williams Development Group, LLC, is part of the company’s strategic efforts to manage its real estate assets effectively.
The most recent analyst rating on (PROK) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on ProKidney stock, see the PROK Stock Forecast page.
Spark’s Take on PROK Stock
According to Spark, TipRanks’ AI Analyst, PROK is a Underperform.
ProKidney’s stock score is significantly impacted by its poor financial performance, characterized by weak revenue growth, high operational costs, and negative cash flow. The technical analysis suggests a bearish trend with mixed indicators, while the valuation reflects high volatility and risk due to negative earnings. Overall, the financial instability and operational challenges are the primary concerns, leading to a low stock score.
To see Spark’s full report on PROK stock, click here.
More about ProKidney
Average Trading Volume: 2,576,740
Technical Sentiment Signal: Buy
Current Market Cap: $894.6M
See more data about PROK stock on TipRanks’ Stock Analysis page.